State Of Wyoming Vanda Pharmaceuticals Inc. Transaction History

State Of Wyoming

$587 Million
Q1 2024

A detailed history of State Of Wyoming transactions in Vanda Pharmaceuticals Inc. stock. As of the latest transaction made, State Of Wyoming holds 11,015 shares of VNDA stock, worth $58,049. This represents 0.01% of its overall portfolio holdings.

Number of Shares

11,015

Previous 33,982 67.59%

Holding current value

$58,049

Previous $143,000 68.53%

% of portfolio

0.01%

Previous 0.03%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$3.47 - $4.61 $79,695 - $105,877	-22,967 Reduced 67.59%	11,015 $45,000
Q4 2023 Feb 14, 2024	BUY	$3.38 - $4.58 $51,338 - $69,565	15,189 Added 80.82%	33,982 $143,000
Q3 2023 Nov 14, 2023	BUY	$4.28 - $6.57 $23,625 - $36,266	5,520 Added 41.59%	18,793 $81,000
Q2 2023 Aug 14, 2023	BUY	$5.9 - $6.95 $50,279 - $59,227	8,522 Added 179.37%	13,273 $87,000
Q1 2023 May 12, 2023	SELL	$6.18 - $7.99 $156,786 - $202,706	-25,370 Reduced 84.23%	4,751 $32,000

Q4 2022 Feb 14, 2023	BUY	$6.87 - $10.96 $66,556 - $106,180	9,688 Added 47.41%	30,121 $222,000
Q3 2022 Nov 14, 2022	BUY	$9.44 - $11.76 $141,779 - $176,623	15,019 Added 277.41%	20,433 $202,000
Q2 2022 Aug 15, 2022	SELL	$9.31 - $11.84 $67,190 - $85,449	-7,217 Reduced 57.14%	5,414 $59,000
Q1 2022 May 13, 2022	SELL	$10.84 - $16.55 $68,487 - $104,562	-6,318 Reduced 33.34%	12,631 $142,000
Q4 2021 Feb 11, 2022	BUY	$15.69 - $21.14 $147,156 - $198,272	9,379 Added 98.0%	18,949 $297,000
Q3 2021 Feb 11, 2022	SELL	$15.35 - $21.27 $9,394 - $13,017	-612 Reduced 6.01%	9,570 $164,000
Q2 2021 Feb 11, 2022	BUY	$15.71 - $21.51 $159,959 - $219,014	10,182 New	10,182 $219,000

Others Institutions Holding VNDA

# of Institutions

148

Shares Held

49.6M

Call Options Held

49.1K

Put Options Held

107K

View Full List

About Vanda Pharmaceuticals Inc.

Ticker VNDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,561,500
Market Cap $298M
Description
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under developme...

More about VNDA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of State Of Wyoming, based on Form 13F filings with the SEC.

News

Stay updated on State Of Wyoming with notifications on news.

Account